Get Alert
Please Wait... Processing your request... Please Wait.
You must sign in to sign-up for alerts.

Please confirm that your email address is correct, so you can successfully receive this alert.

Article   |    
Am J Psychiatry 1956;112:678-683.
View Author and Article Information

The Thudichum Psychiatric Research Laboratory, Galesburg State Research Hospital., Fulbright Fellow, on leave from the Clinic for the Diseases of the Nervous System of the University of Cagliari, Cagliari, Italy.

The Thudichum Psychiatric Research Laboratory, Galesburg State Research Hospital.

text A A A
PDF of the full text article.

1. Clinical evaluations of azacyclonol, reserpine, and chlorpromazine were made in turn on the same group of chronic, moderately disturbed, psychotic patients, most of whom revealed schizophrenic reactions maintained through long hospitalization.2. Beneficial results were obtained with each of the 3 drugs, but not necessarily in the same patients; nor were all patients helped by any one drug.3. Consideration of the total number of patient improvements in our limited series showed reserpine to be best, closely followed by chlorpromazine, and then by azacyclonol.4. From the analysis of the results in relation to the different diagnostic categories, it would seem that the hebephrenic and hebephreno-catatoonic patients were helped most by reserpine, next came azacyclonol, while chlorpromazine was least effective. In the treatment of paranoid patients chlorpromazine was most beneficial, followed by reserpine, and then by azacyclonol. The schizo-affective patients exhibited best improvement with chlorpromazine. One case of involutional depression was strikingly benefited by reserpine.5. Limiting the validity of these conclusions to the types of patients studied we find that it is possible to differentiate between the use of each of these drugs in different psychiatric categories and to indicate the choice of drug that may prove most useful in the treatment of a given case.

Abstract Teaser
Figures in this Article

Your Session has timed out. Please sign back in to continue.
Sign In Your Session has timed out. Please sign back in to continue.
Sign In to Access Full Content
Sign in via Athens (What is this?)
Athens is a service for single sign-on which enables access to all of an institution's subscriptions on- or off-site.
Not a subscriber?

Subscribe Now/Learn More

PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing PsychiatryOnline@psych.org or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).




CME Activity

There is currently no quiz available for this resource. Please click here to go to the CME page to find another.
Submit a Comments
Please read the other comments before you post yours. Contributors must reveal any conflict of interest.
Comments are moderated and will appear on the site at the discertion of APA editorial staff.

* = Required Field
(if multiple authors, separate names by comma)
Example: John Doe

Related Content
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 12.  >
Gabbard's Treatments of Psychiatric Disorders, 4th Edition > Chapter 20.  >
The American Psychiatric Publishing Textbook of Psychiatry, 5th Edition > Chapter 26.  >
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 10.  >
The American Psychiatric Publishing Textbook of Psychopharmacology, 4th Edition > Chapter 54.  >
Topic Collections
Psychiatric News
Read more at Psychiatric News >>
PubMed Articles
The chlorpromazine enigma. J Hist Neurosci 2013;22(1):14-29.